Solus Alternative Asset Management’s Odonate Therapeutics, Inc. Common Stock ODT Stock Holding History

Solus Alternative Asset Management’s Portfolio ODT Stock Details ODT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-100,543	Closed	-$1.42M	–	13
2018 Q4	$1.42M	Sell	100,543 -371,073	-79%	-$5.78M	0.54%	11
2018 Q3	$9.15M	Hold	471,616	–	–	1.67%	9
2018 Q2	$10.4M	Hold	471,616	–	–	2.51%	7
2018 Q1	$9.99M	Hold	471,616	–	–	1.51%	6
2017 Q4	$11.8M	Buy	+471,616	New	+$11.1M	2.29%	6

Other funds holding ODT

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Solus Alternative Asset Management's ODT Position: Q1 2019 in Review

Solus Alternative Asset Management sold out of Odonate Therapeutics, Inc. Common Stock (ODT) in Q1 2019, closing a stake of 100,543 shares — an estimated $1.42M sold.

Solus Alternative Asset Management first reported a position in ODT in Q4 2017 and held it in 5 quarters. The position peaked at $11.8M in Q4 2017. 57 funds tracked by Wall St. Rank hold ODT as of Q1 2019.

Solus Alternative Asset Management reported no remaining Odonate Therapeutics, Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
Solus Alternative Asset Management sold 100,543 Odonate Therapeutics, Inc. Common Stock shares in Q1 2019, an estimated $1.42M.
Solus Alternative Asset Management first reported a position in Odonate Therapeutics, Inc. Common Stock in Q4 2017 and held it in 5 quarters.
Solus Alternative Asset Management's Odonate Therapeutics, Inc. Common Stock position peaked at $11.8M in Q4 2017.
57 funds tracked by Wall St. Rank held Odonate Therapeutics, Inc. Common Stock as of Q1 2019.

Based on Solus Alternative Asset Management's 13F filing for Q1 2019, filed 15 May 2019.